

# COVID-19 Vaccine

<p><b>Vaccine Description</b></p> <p>(See package inserts for specific vaccine components)</p>	<ul style="list-style-type: none"> <li>• mRNA vaccines               <ul style="list-style-type: none"> <li>◦ <a href="#">Pfizer-BioNTech (Comirnaty) 2023-24 Formula Package Insert</a></li> <li>◦ <a href="#">Moderna (Spikevax) 2023-24 Formula Package Insert</a></li> </ul> </li> <li>• Protein subunit vaccine               <ul style="list-style-type: none"> <li>◦ <a href="#">Novavax 2023-24 Formula Package Insert</a></li> </ul> </li> </ul>
<p><b>Route (all)</b></p>	<ul style="list-style-type: none"> <li>• Intramuscular (IM)</li> </ul>
<p><b>Indications</b></p>	<ul style="list-style-type: none"> <li>• Vaccination is recommended for everyone ages 6 months and older in the U.S. for the prevention of COVID-19.</li> </ul>
<p><b>Dosing &amp; Administration</b></p>	<ul style="list-style-type: none"> <li>• <a href="#">Pfizer-BioNTech (Comirnaty) 2023-24 Formula CDC Guidance</a></li> <li>• <a href="#">Moderna (Spikevax) 2023-24 Formula CDC Guidance</a></li> <li>• <a href="#">Novavax 2023-24 Formula CDC Guidance</a></li> </ul>
<p><b>Booster</b></p>	<ul style="list-style-type: none"> <li>• Not applicable; adults are eligible for a single dose of updated (2023-24 Formula) vaccine, regardless of prior COVID-19 vaccine history; immunocompromised adults may receive more than one dose of updated (2023-24 Formula) vaccine, based on CDC guidelines</li> </ul>
<p><b>Contraindications</b></p>	<ul style="list-style-type: none"> <li>• History of severe allergic reaction (e.g., anaphylaxis) after a previous dose or to a component of the COVID-19 vaccine. See the package inserts or EUA Fact Sheet for a list of vaccine components</li> </ul>
<p><b>Precautions</b></p>	<ul style="list-style-type: none"> <li>• History of non-severe allergy to a component of vaccine</li> <li>• History of non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type</li> <li>• Moderate or severe acute illness, with or without fever</li> <li>• History of MISC-A or MISC-C</li> <li>• History of myocarditis or pericarditis within 3 weeks after a dose of any COVID-19 vaccine</li> </ul> <p>Follow <a href="#">CDC Guidance on COVID-19 vaccine precautions</a></p>
<p><b>Adverse Reactions</b></p>	<ul style="list-style-type: none"> <li>• Syncope (fainting) may occur in association with any vaccination.</li> <li>• Local reactions may include pain/tenderness, and, less commonly, swelling, and erythema at the injection site</li> <li>• Systemic reactions may include fever, fatigue/malaise, headache, chills, myalgia, arthralgia</li> <li>• Localized axillary lymphadenopathy may occur on the same side as the vaccinated arm</li> <li>• Infrequently, people who have dermal fillers might experience temporary swelling at or near the site of filler injection</li> <li>• Myocarditis and pericarditis are rare adverse events, especially for males ages 12–39 years. See <a href="#">COVID-19 vaccination and myocarditis and pericarditis</a> for additional information.</li> <li>• Anaphylactic reactions have been rarely reported following receipt of COVID-19 vaccines</li> </ul>

# COVID-19 Vaccine

(Continued)

## Special Considerations

- People who recently had SARS-CoV-2 infection may consider delaying vaccination by 3 months from symptom onset or positive test (if infection was asymptomatic)
- Persons with a history of multisystem inflammatory syndrome, MIS-C (children) or MIS-A (adult), have a precaution to receipt of COVID-19 vaccine and should be referred to a provider for further evaluation
- Development of myocarditis or pericarditis after a dose of an mRNA (Moderna, Pfizer-BioNTech) or Novavax COVID-19 vaccine is a precaution to a subsequent dose of any COVID-19 vaccine and subsequent doses should generally be avoided
- Providers should consider observing people with the following precautions to a previously administered COVID-19 vaccine for 30 minutes if a subsequent dose of the same vaccine type is administered:
  - History of a non-severe, immediate (onset less than 4 hours) allergic reaction after administration of a previous dose of one COVID-19 vaccine type
  - History of a diagnosed non-severe allergy to a component of the COVID-19 vaccine
- Vaccination is recommended for all people aged 6 months and older, including people who are pregnant, breastfeeding, or trying to get pregnant now or who might become pregnant in the future
- COVID-19 vaccines may be co-administered with any other indicated vaccines; no minimum interval applies to receipt of other vaccines with COVID-19 vaccines. People, particularly adolescent and young adult males, who are recommended to receive both COVID-19 and smallpox/mpox vaccines might consider waiting 4 weeks between vaccines. This is because of the observed risk of myo/pericarditis after COVID-19 and ACAM2000 vaccines, and the hypothetical risk of myo/pericarditis after JYNNEOS vaccine. However, if a patient's risk of mpox or COVID-19 severe disease is increased, administration of mpox and COVID-19 vaccines should not be delayed

Screen for contraindications and precautions using [DHA Form 207](#) before administering EACH dose, even if a vaccine was previously administered.

- VIS: <https://www.cdc.gov/vaccines/hcp/vis/vis-statements/covid-19.html>
- Standing Orders: [www.health.mil/standingorders](http://www.health.mil/standingorders)
- ACIP Recommendations: <https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/covid-19.html>
- Additional education: [https://health.mil/COVID19vaccineresources\\_HCP](https://health.mil/COVID19vaccineresources_HCP)